Aarey Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Aarey Drugs Q2 results FY27 announcement is the next scheduled earnings event for Aarey Drugs & Pharmaceuticals Ltd., a manufacturer and trader of bulk drugs and pharmaceutical intermediates, with a large share of revenue coming from traded goods. The stock traded at Rs 98.03 on the NSE on 8 September 2026, up 0.74% from the previous close of Rs 97.31, about 2.0% below its 52-week high of Rs 100.00 and 94.9% above its 52-week low of Rs 50.31.

What makes the Aarey Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 84.16 crore of revenue and a profit of Rs 1.02 crore, while the most recent quarter on record, Q1 FY27, produced Rs 44.63 crore and a profit of Rs 1.02 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Aarey Drugs Q2 Results FY27 Date?

The Aarey Drugs Q2 results date for FY27 is not confirmed. As of 8 September 2026, Aarey Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Aarey Drugs Q2 results date becomes public through that filing rather than through any advance announcement.

The Aarey Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Aarey Drugs.

Aarey Drugs Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Aarey Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Aarey Drugs. The Aarey Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is the revenue collapse in the June quarter. Aarey Drugs reported Rs 44.63 crore against Rs 189.47 crore in the March 2026 quarter, a fall of more than three quarters, and whether September returns to the earlier run rate is the single biggest question in this print.

The second is what that swing says about the business mix. A large traded-goods component makes revenue lumpy because a single bulk transaction can dominate a quarter, so the composition disclosed in the filing matters more than the headline number.

The third is that profit barely moved while revenue collapsed. Net profit was Rs 1.02 crore in June 2026 on revenue of Rs 44.63 crore, and Rs 1.56 crore in March on revenue of Rs 189.47 crore, which points to very different margins on different revenue streams.

Check Aarey Drugs & Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener

Aarey Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 44.63 crore in Q1 FY27, down 56.33% from Rs 102.21 crore in Q1 FY26, and a profit of Rs 1.02 crore at the net level, down 25.55% from Rs 1.37 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was down 76.44% over the March 2026 quarter figure of Rs 189.47 crore, and net profit was down 34.62% from Rs 1.56 crore in Q4 FY26. Operating margin stood at 3.6% in Q1 FY27 against 2.4% in the September 2025 quarter, which is the comparison the Aarey Drugs Q2 results print will be read against.

Q2 FY26 Base: The Comparison Aarey Drugs Q2 Results FY27 Must Beat

Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 84.16 crore and a profit of Rs 1.02 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Aarey Drugs Q2 results preview.

Net profit in that base quarter was below the Rs 1.02 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 84.16 crore sits above the Rs 44.63 crore of the June 2026 quarter, which frames how much sequential movement the Aarey Drugs Q2 results print needs to show growth.

Aarey Drugs Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	84.16	1.02
Q3 FY26 (Dec 2025)	96.43	0.57
Q4 FY26 (Mar 2026)	189.47	1.56
Q1 FY27 (Jun 2026)	44.63	1.02

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Aarey Drugs Q2 results preview uses.

Revenue across those four quarters ranged from Rs 44.63 crore to Rs 189.47 crore, and net profit from Rs 0.57 crore to Rs 1.56 crore. That spread is the honest context for the Aarey Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Aarey Drugs Q2 Results FY27

The Aarey Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Aarey Drugs has already reported.

Traded Versus Manufactured Revenue

Revenue has ranged from Rs 44.63 crore to Rs 189.47 crore in five quarters while profit stayed between Rs 0.57 crore and Rs 1.56 crore. That pattern is typical of a business where low-margin trading inflates the top line without adding much to the bottom line.

Valuation Well Above the Sector

Aarey Drugs trades at a price-to-earnings ratio of 72.34 against a sector average of 37.70, on a return on equity of 2.75%. The stock has also run to a 14-day RSI of 75.53 and sits close to its 52-week high of Rs 100.00, so expectations going into the print are elevated.

Working Capital in a Trading-Led Model

Bulk drug trading absorbs working capital, and receivables and inventory disclosed with the results tell more about cash generation than the profit line does. A debt-to-equity ratio of 0.31 leaves some headroom but not unlimited room.

Aarey Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print

Aarey Drugs share price today is Rs 98.03 on the NSE, up Rs 0.72 or 0.74% from the previous close of Rs 97.31 on 8 September 2026, ahead of the Aarey Drugs Q2 results announcement.

Metric	Value (8 September 2026)
NSE Symbol	AAREYDRUGS
Current Market Price	Rs 98.03
52-Week High	Rs 100.00
52-Week Low	Rs 50.31
Market Capitalisation	Rs 302 crore
PE Ratio	72.34
Sector PE	37.70
PB Ratio	1.85
EPS (TTM)	Rs 1.35
Book Value per Share	Rs 53.00
Debt to Equity	0.31
Return on Equity	2.75%
50-Day Moving Average	Rs 83.21
200-Day Moving Average	Rs 77.07
RSI (14)	75.53

The stock trades above both its 50-day average of Rs 83.21 and its 200-day average of Rs 77.07, with a 14-day RSI of 75.53. None of this is a view on where the shares go once the Aarey Drugs Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Aarey Drugs & Pharmaceuticals Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Aarey Drugs Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Aarey Drugs Q2 results print in proportion.

1. Revenue against the Rs 84.16 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 1.02 crore in that same quarter
3. Operating margin against 3.6% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Aarey Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Aarey Drugs Q2 Results FY27

The Aarey Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Aarey Drugs & Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Aarey Drugs Q2 results FY27 print faces a base of Rs 84.16 crore in revenue and a profit of Rs 1.02 crore, with the most recent quarter having delivered Rs 44.63 crore and a profit of Rs 1.02 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Aarey Drugs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Aarey Drugs Q2 Results FY27

What is the Aarey Drugs Q2 results date for FY27?

Ans. The Aarey Drugs Q2 results date for FY27 is not confirmed. Aarey Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Aarey Drugs Q2 results 2026 cover?

Ans. The Aarey Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aarey Drugs & Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Aarey Drugs Q2 results filing also carries the notes to the accounts.

What were the Aarey Drugs Q1 FY27 results?

Ans. Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 44.63 crore in Q1 FY27 and a profit of Rs 1.02 crore at the net level. Revenue was down 56.33% versus Q1 FY26 and net profit was down 25.55% from Rs 1.37 crore in Q1 FY26.

What were Aarey Drugs Q2 FY26 results in the September 2025 quarter?

Ans. Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 84.16 crore and a profit of Rs 1.02 crore in Q2 FY26. Operating margin was 2.4%. Those figures form the base for the Aarey Drugs Q2 results FY27 comparison.

What are the main Aarey Drugs Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Aarey Drugs Q2 results expectations centre on revenue against the Rs 84.16 crore base, net profit against a profit of Rs 1.02 crore, operating margin against 3.6% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Aarey Drugs share price today ahead of the Q2 earnings?

Ans. Aarey Drugs share price is Rs 98.03 on the NSE as of 8 September 2026, up 0.74% from Rs 97.31. The stock is about 2.0% below its 52-week high of Rs 100.00 and 94.9% above its 52-week low of Rs 50.31, at a market capitalisation of Rs 302 crore.

Is Aarey Drugs a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Aarey Drugs & Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 1.85 with a return on equity of 2.75%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.